Specialists across the Commonwealth (Canada, New Zealand and Australia) shared the latest advancements in treatments, research, and patient support for those diagnosed with NETs. NeuroEndocrine Cancer Australia proudly presented an Australian update, ongoing clinical trials, government lobbying, education and key initiatives like the AUS-NET program and the PLANET registry, which play vital roles in improving outcomes for NET patients nationwide. Other presentations highlighted cutting-edge research in genomics and Theranostics. CommNETs also provides the opportunity to have working groups to develop international guidelines, one of which is nutrition guidelines for NETs.
The Australian delegation (13 in total) included Meredith Cummins (NECA CEO), Erin Laing and Caley Schnaid (Dietitians), Dr. David Chan (Medical Oncologist and NECA Board Member), A/Prof Gabby Cehic AM (Nuclear Med Physician), A/Prof Grace Kong (Nuclear Med Physician) A/Prof David Wyld (Medical Oncologist) and Professor Michael Michael (Medical Oncologist). Together, they showcased Australia’s leadership in NET advocacy and care, underlining the importance of ensuring patients, regardless of their location, have access to the latest knowledge and support.
This global workshop provided a valuable opportunity to meet with peers from around the world, exchange ideas, and share experiences. The collaborative spirit highlights the power of working together as a diverse multidisciplinary team to bridge gaps and improve outcomes in NET patient care. By sharing global expertise and taking proactive steps to reach patients Australia continues to deliver equitable, patient-centred optimal care.
